Pfizer (PFE) has begun its first human trials of a gene therapy to treat Duchenne muscular dystrophy, following two other companies that have launched trials and one treatment for the disease in recent years.
The first patient received the experimental therapy, called PF-06939926, on March 22, Pfizer said Thursday. The study is expected to run through 2019 and to enroll about a dozen boys from 5 to 12 years old at four sites.
About the Author Reprints
my son 4 year Muscular dystrophy patient please help me I am for India
Treatment for muscular dystrophy limb gridle